Koers Biofrontera AG OTC Markets
Aandelen
BFRA
US09075G1058
Farmaceutische producten
Omzet 2021 | 28,79 mln. 31,14 mln. | Omzet 2022 | 25,74 mln. 27,84 mln. | Marktkapitalisatie | 97,31 mln. 105 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | 38 mln. 41,11 mln. | Nettowinst (verlies) 2022 | -44 mln. -47,6 mln. | EV/omzet 2021 | 2,79 x |
Nettoliquiditeiten 2021 | 3,61 mln. 3,9 mln. | Nettoliquiditeiten 2022 | 4,88 mln. 5,27 mln. | EV/omzet 2022 | 3,59 x |
K/w-verhouding 2021 |
2,18
x | K/w-verhouding 2022 |
-1,98
x | Werknemers | 92 |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 32,4% |
Recentste transcriptie over Biofrontera AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Director of Finance/CFO | 55 | 12-09-22 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 63 | 14-12-21 | |
Director/Board Member | - | 14-12-21 | |
Heikki Lanckriet
BRD | Director/Board Member | 46 | 14-12-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,98% | 682 mld. | |
+30,80% | 586 mld. | |
-3,52% | 364 mld. | |
+18,59% | 327 mld. | |
+4,07% | 285 mld. | |
+16,77% | 240 mld. | |
+9,82% | 209 mld. | |
-8,34% | 203 mld. | |
+7,09% | 165 mld. |